


Monitoring and Evaluation of HIV Viral Load Programs

Robert Luo, MD, MPH Diagnostics Consultant, WHO



Global Indicators for HIV Monitoring and Evaluation





Key Variables for Laboratories to Consider

Specimen requisition form (entered at the clinic)

- Patient identification number
- Collection site
- Date of birth (age)
- Sex
- Whether currently pregnant or breastfeeding
- If receiving antiretroviral therapy, current regimen (first, second or third line)
- Previous exposure to antiretroviral drugs, such as for preventing mother-to-child transmission, post-exposure prophylaxis or pre-exposure prophylaxis
- Date antiretroviral therapy started (time receiving antiretroviral therapy)
- Reason for the test
- Date and time specimen collected
- Specimen type
- Adherence assessment
- WHO clinical staging and DC4 count

Testing requisition form (entered at the laboratory)

- Demographic information (patient identification number, specimen identification number, date of birth, current antiretroviral therapy regimen)
- Result of the viral load test, including which assay (copies/ mL)
- Specimen quality
- Temperature at which the specimen was received
- Date and time the specimen was received
- Date the specimen was tested
- Date the result was reported



Viral Load Testing Cascade

Number of people living with HIV receiving antiretroviral therapy Number of people living with HIV receiving antiretroviral therapy who require at least one^a routine annual viral load test (depending on the viral load algorithm)

Number of people living with HIV receiving antiretroviral therapy who have access to viral load testing

Number of people living with HIV receiving antiretroviral therapy who received a viral load test

Number of people living with HIV receiving antiretroviral therapy who have suppressed viral loads Number of people living with HIV with suppressed viral loads referred to a less intensive model of care



Core Indicators Along the Cascade

Key steps in the cascade of viral load testing	Core indicators for routine monitoring (see Annex 5 for more detailed indicator information, including numerator and denominator guidance)
Order viral load test	 % of sites in the specimen transport network that are submitting samples for viral load testing Number of viral load tests submitted by sites to the laboratory and specimen transport network
Process viral load test sample	 Number of viral load tests received by the laboratory from sites Number of viral load tests run by the laboratory
Returned viral load test result	 % of viral load tests results returned to sites within one month of the sample being taken





Core Indicators Along the Cascade

Coverage, documentation and outcome of viral load test result	 % of people receiving antiretroviral therapy with viral load results at 12 months after initiating antiretroviral therapy [WHO: VLS.2]
	 % of people receiving antiretroviral therapy tested for viral load with level <1000 copies/mL at 12 months after antiretroviral therapy initiation [WHO: VLS.1]
	 % of people with a viral load result documented in the medical records and/or laboratory information systems within the past 12 months with a suppressed viral load (<1000 copies/mL) [PEPFAR MER: TX_PVLS]
	 % of people living with HIV receiving antiretroviral therapy who have suppressed viral loads [WHO VLS.3]
	 % of people living with HIV with suppressed viral loads (<1000 copies/mL) who have been referred to a less intense model of care or differentiated service delivery
Intervene on viral load test result if viral load ≥1000 copies/mL	 % of people receiving antiretroviral therapy with viral load ≥1000 copies/mL who have received enhanced adherence counselling






Core Indicators Along the Cascade

Order follow-up viral load test if viral load ≥1000 copies/mL	 % of people receiving antiretroviral therapy with viral load ≥1000 copies/mL who received a follow-up viral load test within 3–6 months after enhanced adherence counselling (or according to the national guidelines) % of people receiving antiretroviral therapy who had viral load ≥1000 copies/mL and then had suppressed viral load <1000 copies/mL on follow-up testing
Modify antiretroviral therapy regimen after two consecutive results of viral load ≥1000 copies/ mL	 % of people living with HIV receiving antiretroviral therapy with two documented viral load test results ≥1000 copies/mL switched to second- or third-line antiretroviral therapy regimens





Viral Load Testing Cascade





Evaluating Service Quality and Viral Load Testing

- Assess compliance with national guidelines on viral load monitoring
 Site level with viral load testing, follow-up and referrals
- Assess compliance with national guidelines on managing treatment
 - If treatments are being changed in a timely manner to second-line regimens when necessary in accordance with guidelines



Process Evaluations

Examples of questions	Use of results
 Were target populations reached? Why not? Was the programme implemented as planned? Why? What worked? What did not work? What were the kinds of problems encountered in delivering the programme – were there enough resources from the beginning to do it well? Was it well managed? Were staff trained or educated to the right level of the programme design? Is there skill at facilitating the 	 Decision-making Resource allocation Programme improveme Understand how programme impact and outcome were achieved (programme implementation) to inf programme replication

programme processes from beginning to end? Was there adequate support for the programme?

- nent
- form




Outcome Evaluations

- Were the intended effects (outcomes) achieved? What contributed to that?
- Was the programme more successful with certain groups of people than with others?
- What aspects of the programme did participants find gave the greatest benefit?
- Did implementing the intervention result in changes in knowledge, attitudes and skills among the members of the target population?
- Did the programme have any unintended (beneficial or adverse) effects on the target populations?
- How has the intervention changed the quality of services?

- Decision-making
- Resource allocation
- Programme improvement
- Determine whether programme effectiveness has been demonstrated and whether the programme objectives were met



Example Data Summary





Sample Patient Register

HMIS FORM 081: ART REGISTER

COHORT: Year



(19)

3rd-line regimen

(18)

2nd-line regimen

	. A. M. M.									17 B									: constant a subset of the second	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	11	(12)	(13)	(14)	(15)		(16	5)			(17)
			Re	gistration and personal	info	ormati	on	St	atus at s	tart /	ART	CLINICAL STAGE (Insert date)				eMTC	ст		Original Regimen	1st-line regimen
ART start	Unique ID No.	MTCT	nic ID	Name Surname	Sex	Age	Address (District, sub-	Function status	Weight/ MUAC	Istage	4 # /%	CPT/ Dapsone Start Month	INH (H) Start Month/	TB Rx District TB reg # Start Month / year	EDD. AN		gnancy, rec V-exposed			1st: Reason/ Dat
date		TI / el	oli D	Given name		(yra) (Write age months if 2	county, parish, LC1)	E I		WHO	G	/year Stop Month /year	year Stop Month/ year	Stop Month / year		Preg 2	Preg 3	Preg 4		2nd: Reason/ Dat
				Sumama	Γ		District					Start Date	Start Date	REG #	EDD	EDD	EDD	EDD		1st:

Name of Health Unit

start	ID No.	MTC.	atient nic IC	Surname 0	(yra) rho ago in the if 2 yre)	(District, sub-	nctior	MUAC	l stag	4			District TB reg # Start Month / year			gnancy, rec IV-exposed		Reason/ Date	Reason/ Date	Reason/ Date
date		TI / e	G P	Given name	() (Wrfto z months if	county, parish, LC1)	Ъ.s		WHO	9	/year Stop Month /year	year Stop Month/ year	Stop Month / year	Preg 1	Preg 2	Preg 3	Preg 4	2nd: Reason/ Date	2nd: Reason/ Date	2nd: Reason/ Date
				Surname Given name		District Sub-County, Parist/ Village / Cell					Start Date Stop Date	Start Date Stop Date	REG # Start Date Stop Date	EDD ANC Infant #	EDD ANC Infant #	EDD ANC Infant #	EDD ANC Infant #	1st: Reason / Date 2nd: Reason / Date	1st: Reason / Date 2nd: Reason / Date	1st: Reason / Date 2nd: Reason / Date
				Surname Given name		District Sub-County, Parish/ Village / Cell														
				Surname Given name		District Sub-County, Parish/ Village / Cell					Start Date	Start Date	REG # Start Date Stop Date	EDD ANC Infant #	EDD ANC Infant #	EDD ANC Infant #	EDD ANC Infant #	1st: Reason / Date 2nd: Reason / Date	1st: Reason / Date 2nd: Reason / Date	1st: Reason / Date 2nd: Reason / Date
				Surname Given name		District Sub-County, Parish/ Village / Cell														
				Surname Given name		District Sub-County, Parist/ Village / Cell					Start Date Stop Date	Start Date Stop Date	REG # Start Date Stop Date	EDD ANC Infant #	EDD ANC Infant #	EDD ANC Infant #	EDD ANC Infant #	1st: Reason / Date 2nd: Reason / Date	1st Reason / Date 2nd: Reason / Date	1st: Reason / Date 2nd: Reason / Date
				Surname Given name		District Sub-County, Parish/ Village / Cell														

Right side of register

HMIS FORM 081: ART REGISTER



COHORT: Ye Name of Health Uni

		Year	Fi	ll in Months								Fill in Mo	onths						
	Patient ID	Month 0	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Clinical stage	Wgt	CD4# CD4% VIRAL LOAD	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12	Clinical stage	
		ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVe/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT			CD4# CD4% VIRAL LOAD	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT		CE				
_		ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT			CD4# CD4% VIRAL LOAD	ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVa/FU Status TB Status / Nutrition Status ADH CPT		CD
		ARVa/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status T8 Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVe/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutnition Status ADH CPT			CD4# CD4% VIRAL LOAD	ARVs/FU Status TB Status / Nutrition Statue ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVe/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT		CE
loł tic		ARVs/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Statua ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT			CD4# CD4% VIRAL LOAD	ARVE/FU Status TB Status / Nutrition Status ADH CPT	ARVs/FU Status TB Status / Nutrition Status ADH CPT		CE								



Sample Laboratory Reporting Form

FACILITY DETAILS

ame:		
istrict.	L Hub:	

PATIENT INFORMATION

ART	Number:	
ART	Number:	

Other ID:

Sex: Female Male Left Blank

Date of Birth: ____

Phone	Number:

TREATMENT INFORMATION

Treatment Initiation date:				Treatment Line:	First	Second	Third
Pregnant?:	NO	YES	ANC #:				
Breastfeeding? :	NO	YES					

VIRAL LOAD RESULTS

Method Used:	HIV-1 RNA PCR Roche	
Location ID:		
Viral Load Testing #:		
Result of Viral Load:		

SAMPLE DETAILS

DBS

SAMPLE TEST INFORMATION

Sample Collection Date:

Reception Date: Test Date: Plasma

Form #: Sample Type:

RECOMMENDATIONS

Suggested Clinical Action based on National Guidelines:

- ≥ 1,000 copies/mL. Patient has unsuppressed viral load.
 - Please screen/test for OI- crag and initiate intensive adherence counseling
 - Repeat viral load test within 4 6 months.
 - Next VL test Expected in Oct, 2016. Send 2 samples. One for VL test. One for HIVDR test





Department of Global HIV, Hepatitis Transmitted Infection Programmes

Lab

101-100

Sample High Viral Load Follow-Up Register

	PATIENT SURNAME	PATIENT FIRST NAME	ART NUMBER	ART START DATE	DOB	SEX	CURRENT ART REGIMEN	REASON FOR VL TEST	DATE FIRST VL TAKEN	DATE RESULTS RECEIVED BY FACILITY	DATE PATIENT RECEIVED HIGH VL RESULT	FIRST EAC SESSION DATE	SECOND EAC SESSION DATE	THIRD EAC SESSION DATE	ADDITIONAL EAC SESSION DATE	ADDITIONAL EAC SESSION DATE
1.																
2.																
3.																
4.																
5.																
6.																
7.																



Planning for Monitoring and Evaluation

Evaluation plan matrix

Evaluation questions	Type of evaluation	Variables and indicators	Data sources	Data collection method	Dissemination and use
What do we need to know or evaluate (fidelity and effectiveness) about the programme?	What type of evaluation is it? Process? Outcome? Both?	What specific variables and indicators are needed to answer your evaluation question?	What will the data source be for the variables and indicators?	How will the data be collected? Qualitative, quantitative or mixed methods? Will interviews, document reviews and/ or reviews of programme data occur?	What dissemination and use strategies will be used to share evaluation findings? How will stakeholders use them to improve programmes? Make sure to include where the evaluation findings will be publicly available (for PEPFAR- supported evaluations)



